We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
NK (Common Stock) $3.780.00 (0.00%)
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs

May 18, 2017 | Press Releases

Company Adds Immuno-Oncology and Clinical Trial Expert to Leadership Team

Read More

NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology

May 16, 2017 | Press Releases

Company adds esteemed pediatric, adolescent and young adult oncology expert to

Read More

NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference

May 15, 2017 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--May 15, 2017-- NantKwest (Nasdaq:NK), a l

Read More

Upcoming Events
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.